

CIA protocol in DBA mice: mouse model for rheumatoid arthritis
"prophylactic regimen":
day 0
immunize with bovine collagen and CFA
day 21
immunize with bovine collagen and IFA
"therapeutic regimen":
test reagent:
day 21 start, 200 ug/mouse, 2x/week
test reagent:
first indications of disease at around day 23
sac around day 40 or later

FIG. 1




FIG. 2

first expt: therapeutic regimen




first expt: prophylactic regimen
Mean Total Body Score
0
1
2
3
4
5
6
7
8
DAY 24
DAY 27
DAY 29
DAY 31
DAY 34
DAY 36
control human IgG
rat anti-GIL19

FIG. 3

FIG. 4

second expt: prophylactic regimen (with more severe disease)





first expt: prophylactic regimen
% of paws
80
60
40
20
0
rat anti-GIL19
control human IgG
0
1
2
3
4
no disease
severest disease
histology grade

FIG. 5

Figure 6A




Figure 6B




FIGURE 6A – 6B

Figure 7A




Figure 7B




FIGURE 7A – 7B

Figure 8A




Figure 8B




FIGURE 8A – 8B

Figure 9A




Figure 9B




FIGURE 9A – 9B

Figure 10A




Figure 10B




Figure 10C




FIGURE 10A-10C

Figure 11A




Figure 11B




Figure 11C




FIGURE 11A – 11C

SUBSTITUTE SHEET (RULE 26)



IL-22R
binding site
IL-22
IL-10R2
binding site
IL-22BP, Ab-04
Ab-02
IL-22R
IL-10R2

FIGURE 12



7000
6000
5000
4000
3000
2000
1000
0
Luc. Unit
0.1
1
10
100
1000
Ab (nM)

FIGURE 13




FIGURE 14



60000
50000
40000
30000
20000
10000
0
Luminance reading
0.1
1
10
100
1000
Antibody (nM)

FIGURE 15